EXPEDITION

CompletedPhase 3

Effect of LY2062430 on the Progression of Alzheimer's Disease

Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo

Lead sponsor

Eli Lilly and Company

Asset

Solanezumab

Listed sites

Recruiting sites

Enrollment

1,000

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•MMSE 16-26•MRI contraindications excluded

Primary endpoints

•ADAS-Cog•ADCS-Activities of Daily Living (ADCS-ADL)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID6747

Secondary IDH8A-MC-LZAMEli Lilly and Company

NCT IDNCT00905372

Timeline

Milestones

Study start2009-05 (month precision)

Study first posted2009-05-20estimated

Primary completion2012-04actual (month precision)

Study completion2012-04actual (month precision)

Last update posted2012-09-25estimated

Assets

Drug assets

Solanezumab

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Meets criteria for mild to moderate Alzheimer's Disease (AD) with Mini-Mental State Examination score of 16 through 26 at screening

•Modified Hachinski Ischemia Scale score of less than or equal to 4

•Geriatric Depression Scale score of less than or equal to 6

•A magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2 years with no findings inconsistent with a diagnosis of AD

•If receiving concurrent AD treatment, must be on the medication for at least 4 months at a stable dose for at least 2 months prior to randomization

Exclusion criteria

•Has serious or unstable illness(es)

•Does not have a reliable caregiver who is in frequent contact with patient (at least 10 hours per week)

•Meets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia

•Does not have good venous access, such that intravenous (IV) drug delivery would be difficult

•Has had multiple episodes of head trauma or history within the last 5 years of a serious infectious disease affecting the brain

•Has allergies to humanized monoclonal antibodies

•Chronic alcohol and/or drug abuse within the past 5 years

•Has any contraindications for MRI studies

•Requires treatment with another monoclonal antibody

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Caregiver / quality of life

Other (unclassified)

Global cognition

Function / daily living

Behavior / neuropsychiatric

Neuroimaging

Global cognition

2 endpoints

Secondary/protocol endpoint

Change from baseline to endpoint in Clinical Dementia Rating-Sum of Boxes (CDR-SB)

Time frame:Baseline, 80 weeks

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline to endpoint in Mini-Mental State Examination (MMSE)

Time frame:Baseline, 80 weeks

Mini-Mental State Examination (MMSE)

change from baseline, improvement

Function / daily living

1 endpoint

Primary/protocol endpoint

Change from baseline to endpoint in Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL)

Time frame:Baseline, 80 weeks

ADCS-Activities of Daily Living (ADCS-ADL)

change from baseline, improvement

Behavior / neuropsychiatric

1 endpoint

Secondary/protocol endpoint

Change from baseline to endpoint in Neuropsychiatric Inventory (NPI)

Time frame:Baseline, 80 weeks

Neuropsychiatric Inventory (NPI)

change from baseline, improvement

Neuroimaging

1 endpoint

Secondary/protocol endpoint

Change from baseline to endpoint in volumetric magnetic resonance imaging (vMRI)

Time frame:Baseline, 80 weeks

change from baseline, improvement

Caregiver / quality of life

3 endpoints

Secondary/protocol endpoint

Change from baseline to endpoint in Resource Utilization in Dementia-Lite (RUD-Lite)

Time frame:Baseline, 80 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline to endpoint in EuroQol 5-Dimensional Health-related Quality of Life Scale Proxy version (EQ-5D Proxy)

Time frame:Baseline, 80 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change from baseline to endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)

Time frame:Baseline, 80 weeks

change from baseline, improvement

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

Change from baseline to endpoint in Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11)

Time frame:Baseline, 80 weeks

ADAS-Cog

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline to endpoint in plasma LY2062430 to investigate a relationship between plasma LY2062430 and plasma A Beta levels.

Time frame:Baseline, 80 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from baseline to endpoint in plasma A Beta

Time frame:Baseline, 80 weeks

change from baseline, improvement

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.